Prenatal Second-Hand Smoke Exposure Measured with Urine Cotinine May Reduce Gross Motor Development at 18 Months of Age - 23/07/15

Abstract |
Objective |
To evaluate the association of second-hand smoke exposure of pregnant mothers using urine cotinine with the neurodevelopment of their children at 18 months of age in the mother-child cohort in Crete (Rhea Study).
Study design |
Selected participants were Greek mothers with singleton pregnancies, had never smoked, and had available urine cotinine measurements in pregnancy, and their children for whom a neurodevelopmental assessment was completed. We performed face-to-face interviews twice during pregnancy and postnatally, and assessed children's neurodevelopment at 18 months of age using the Bayley Scales of Infant and Toddler Development, Third Edition. We used linear regression and generalized additive models.
Results |
Of 599 mothers, 175 (29%) met the inclusion criteria. Maternal urine cotinine levels were low (mean: 10.3 ng/mL, SD: 11.7 ng/mL). Reported passive smoking from different sources was strongly associated with urine cotinine levels. A negative association was observed between cotinine levels in pregnancy and child's gross motor function (beta = −3.22 per 10 ng/mL, 95% CI −5.09 to −1.34) after adjusting for factors potentially associated with neurodevelopment; results were similar in both sexes. A negative association was also observed for cognitive and receptive communication scales but the effect was small and not statistically significant.
Conclusions |
Maternal exposure during pregnancy to second-hand smoke measured through urine cotinine was associated with a decrease in gross motor function among 18-month-old children, even at low levels of exposure.
Le texte complet de cet article est disponible en PDF.Keyword : Bayley-III, SHS
Plan
| Supported by the Flight Attendant Medical Research Institute (Clinical Investigator Award 072058), the European Union (Integrated Project NewGeneris, FP6 [contract Food-CT-2005-016320]; HiWATE, FP6 [contract Food-CT-2006-036224]; EnviroGenoMarkers (FP7 [contract 226756]). The authors declare no conflicts of interest. |
Vol 167 - N° 2
P. 246 - août 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
